WO2002060919A3 - Molecules with extended half-lives, compositions and uses thereof - Google Patents
Molecules with extended half-lives, compositions and uses thereof Download PDFInfo
- Publication number
- WO2002060919A3 WO2002060919A3 PCT/US2001/048432 US0148432W WO02060919A3 WO 2002060919 A3 WO2002060919 A3 WO 2002060919A3 US 0148432 W US0148432 W US 0148432W WO 02060919 A3 WO02060919 A3 WO 02060919A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molecules
- lives
- compositions
- fcrn
- proteins
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 abstract 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19153658.0A EP3569610A3 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half lives, compositions and uses thereof |
DE60143544T DE60143544D1 (en) | 2000-12-12 | 2001-12-12 | MOLECULES WITH LONGER MID-TERM, COMPOSITIONS AND THEIR USE |
EP10010679.8A EP2341060B1 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
AT01997063T ATE489395T1 (en) | 2000-12-12 | 2001-12-12 | MOLECULES WITH LONGER HALF-LIFE, COMPOSITIONS AND THEIR USE |
DK01997063.1T DK1355919T3 (en) | 2000-12-12 | 2001-12-12 | Molecules with longer half-lives, compositions and uses thereof |
CA2431600A CA2431600C (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
JP2002561487A JP4336498B2 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-life and compositions and uses thereof |
AU2002248184A AU2002248184C1 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
EP01997063A EP1355919B1 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
AU2008201419A AU2008201419C1 (en) | 2000-12-12 | 2008-03-27 | Molecules with extended half-lives, compositions and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25488400P | 2000-12-12 | 2000-12-12 | |
US60/254,884 | 2000-12-12 | ||
US28976001P | 2001-05-09 | 2001-05-09 | |
US60/289,760 | 2001-05-09 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002060919A2 WO2002060919A2 (en) | 2002-08-08 |
WO2002060919A9 WO2002060919A9 (en) | 2003-01-03 |
WO2002060919A3 true WO2002060919A3 (en) | 2003-09-04 |
Family
ID=26944296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/048432 WO2002060919A2 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (8) | US7083784B2 (en) |
EP (5) | EP2341060B1 (en) |
JP (7) | JP4336498B2 (en) |
AT (1) | ATE489395T1 (en) |
AU (1) | AU2002248184C1 (en) |
CA (1) | CA2431600C (en) |
CY (1) | CY1111283T1 (en) |
DE (1) | DE60143544D1 (en) |
DK (1) | DK1355919T3 (en) |
ES (2) | ES2727425T3 (en) |
PT (1) | PT1355919E (en) |
WO (1) | WO2002060919A2 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US8524867B2 (en) | 2006-08-14 | 2013-09-03 | Xencor, Inc. | Optimized antibodies that target CD19 |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8937158B2 (en) | 2003-03-03 | 2015-01-20 | Xencor, Inc. | Fc variants with increased affinity for FcγRIIc |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
Families Citing this family (746)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US7183387B1 (en) * | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR100940380B1 (en) * | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | Polypeptide Variants with Altered Effector Function |
DE60142614D1 (en) * | 2000-01-27 | 2010-09-02 | Medimmune Inc | INITÄT |
US7700735B2 (en) * | 2000-03-01 | 2010-04-20 | Medimmune, Llc | High potency recombinant antibodies and method for producing them |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7179900B2 (en) * | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US20080254027A1 (en) * | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
JP4557714B2 (en) * | 2002-05-10 | 2010-10-06 | メディミューン,エルエルシー | EphA2 monoclonal antibody and method of use thereof |
US20040091486A1 (en) * | 2002-05-10 | 2004-05-13 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
SI1562972T1 (en) * | 2002-10-15 | 2010-12-31 | Facet Biotech Corp | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
WO2004062619A2 (en) | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF |
CN1798767B (en) * | 2003-04-10 | 2011-02-16 | 晶面生物技术公司 | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2004091375A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2 and non-neoplastic hyperproliferative cell disorders |
CA2521826C (en) * | 2003-04-11 | 2013-08-06 | Jennifer L. Reed | Recombinant il-9 antibodies and uses thereof |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
KR20120090094A (en) * | 2003-06-13 | 2012-08-16 | 바이오겐 아이덱 엠에이 인코포레이티드 | Aglycosyl anti-cd154(cd-40 ligand) antibodies and uses thereof |
JP4178514B2 (en) * | 2003-06-27 | 2008-11-12 | 東洋紡績株式会社 | Antibody screening method |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
PL2520654T3 (en) | 2003-08-26 | 2017-08-31 | The Regents Of The University Of Colorado, A Body Corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
WO2005037867A1 (en) * | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
WO2005063815A2 (en) * | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
US20050249723A1 (en) * | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
CA2561264A1 (en) * | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
CA2562771C (en) | 2004-04-12 | 2013-04-09 | Medimmune, Inc. | Anti-il-9 antibody formulations and uses thereof |
CN102973947A (en) | 2004-06-01 | 2013-03-20 | 健泰科生物技术公司 | Antibody-drug conjugates and methods |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
CA2575838A1 (en) | 2004-07-26 | 2006-03-30 | Biogen Idec Ma Inc. | Anti-cd154 antibodies |
ES2426816T3 (en) | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Fc regions variants |
EP1784424A4 (en) * | 2004-08-16 | 2009-03-18 | Medimmune Inc | Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
ZA200701715B (en) * | 2004-08-19 | 2008-07-30 | Genentech Inc | Polypeptide variants with altered effector function |
WO2006031994A2 (en) * | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
JP2008518023A (en) | 2004-10-27 | 2008-05-29 | メディミューン,インコーポレーテッド | Regulation of antibody specificity by altering affinity for cognate antigens |
AU2005302453A1 (en) * | 2004-10-29 | 2006-05-11 | Medimmune, Llc | Methods of preventing and treating RSV infections and related conditions |
EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | Engineering fc antibody regions to confer effector function |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1772465B1 (en) | 2005-01-05 | 2009-02-18 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
CA2595169A1 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
NZ556065A (en) * | 2005-01-24 | 2009-04-30 | Univ Texas | FC-fusion constructs binding to phosphatidylserine and their therapeutic use |
CA2597924C (en) | 2005-02-15 | 2018-10-02 | Duke University | Anti-cd19 antibodies and uses in oncology |
US8999943B2 (en) | 2005-03-14 | 2015-04-07 | Board Of Regents, The University Of Texas System | Antigene oligomers inhibit transcription |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP1868650B1 (en) | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
JP5255435B2 (en) | 2005-04-26 | 2013-08-07 | メディミューン,エルエルシー | Regulation of antibody effector function by hinge domain manipulation |
AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
BRPI0611069A2 (en) | 2005-05-06 | 2010-11-09 | Zymogenetics Inc | monoclonal antibody, humanized antibody, antibody fragment, use of an antagonist, and hybridoma |
WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
EP1899477A4 (en) * | 2005-07-01 | 2010-01-20 | Medimmune Inc | An integrated approach for generating multidomain protein therapeutics |
CA2652434A1 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized proteins that target ep-cam |
CA2618681C (en) | 2005-08-10 | 2015-10-27 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
CA2625619A1 (en) | 2005-10-14 | 2007-04-26 | Medimmune, Inc. | Cell display of antibody libraries |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
AU2006336624B2 (en) | 2005-11-17 | 2010-11-25 | Board Of Regents, The University Of Texas System | Modulation of gene expression by oligomers targeted to chromosomal DNA |
BRPI0619056A2 (en) * | 2005-11-28 | 2011-09-20 | Genmab As | monovalent antibody, method for preparing and producing a monovalent antibody, nucleic acid construct, host cell, immunoconjugate, use of a monovalent antibody, and pharmaceutical composition |
DK1963369T3 (en) | 2005-11-28 | 2013-06-03 | Zymogenetics Inc | IL-21 Antagonists |
JP5808070B2 (en) | 2005-12-02 | 2015-11-10 | ジェネンテック, インコーポレイテッド | Binding polypeptides and uses thereof |
WO2007092772A2 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
EP2650306A1 (en) | 2006-03-06 | 2013-10-16 | Aeres Biomedical Limited | Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
CN105177091A (en) * | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | Antibody modification method for purifying bispecific antibody |
WO2007114319A1 (en) * | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | Method for control of blood kinetics of antibody |
ES2567402T3 (en) | 2006-05-30 | 2016-04-22 | Genentech, Inc. | Anti CD22 antibodies, their immunoconjugates and their uses |
EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
HUE030269T2 (en) | 2006-06-26 | 2017-04-28 | Macrogenics Inc | Fc riib-specific antibodies and methods of use thereof |
AT503902B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING IMMUNE LOBULINS |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
AT503861B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING T-CELL RECEPTORS |
CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
CA2658612C (en) | 2006-08-03 | 2015-11-17 | Astrazeneca Ab | Antibodies directed to .alpha.v.beta.6 and uses thereof |
JP5638804B2 (en) | 2006-08-04 | 2014-12-10 | アストラゼネカ アクチボラグ | Antibodies against ErbB2 |
EP2759549B1 (en) | 2006-09-01 | 2015-08-19 | ZymoGenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
ATE551071T1 (en) | 2006-09-08 | 2012-04-15 | Medimmune Llc | HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATION AND AUTOIMMUNE DISEASES |
JP2010506842A (en) * | 2006-10-16 | 2010-03-04 | メディミューン,エルエルシー | Molecules with reduced half-life, compositions thereof and uses |
US8436147B2 (en) | 2006-10-27 | 2013-05-07 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
EP2687232A1 (en) | 2006-12-06 | 2014-01-22 | MedImmune, LLC | Methods of treating systemic lupus erythematosus |
US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
KR20150097813A (en) | 2006-12-19 | 2015-08-26 | 제넨테크, 인크. | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
CA2679986C (en) | 2007-03-08 | 2018-03-06 | Martin Lackmann | Epha3 antibodies for the treatment of solid tumors |
EP1980269A1 (en) * | 2007-04-13 | 2008-10-15 | Katholieke Universiteit Leuven | Prevention of staphylococcus biofilm formation |
WO2008137915A2 (en) | 2007-05-07 | 2008-11-13 | Medimmune, Llc | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
AU2008260498B2 (en) | 2007-05-30 | 2012-11-29 | Xencor, Inc. | Methods and compositions for inhibiting CD32b expressing cells |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US7580304B2 (en) * | 2007-06-15 | 2009-08-25 | United Memories, Inc. | Multiple bus charge sharing |
JP5602625B2 (en) | 2007-06-26 | 2014-10-08 | エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング | Binding substance display |
WO2009006520A1 (en) * | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
PE20140196A1 (en) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | ANTI-CD37 ANTIBODIES |
EP2190987B1 (en) * | 2007-08-21 | 2012-11-14 | MorphoSys AG | Methods for the formation of disulphide bonds |
EP3789400A1 (en) | 2007-09-26 | 2021-03-10 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
EP2202245B1 (en) | 2007-09-26 | 2016-08-24 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
SI2219452T1 (en) | 2007-11-05 | 2016-03-31 | Medimmune, Llc | Methods of treating scleroderma |
EP2219672B1 (en) | 2007-11-09 | 2016-02-17 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
WO2010055366A2 (en) | 2007-12-07 | 2010-05-20 | Zymogenetics, Inc. | Anti-human il-21 monoclonal antibodies |
ES2570853T3 (en) | 2007-12-07 | 2016-05-20 | Zymogenetics Inc | Humanized antibody molecules specific for IL-31 |
WO2009117030A2 (en) | 2007-12-19 | 2009-09-24 | Macrogenics, Inc. | Improved compositions for the prevention and treatment of smallpox |
CA2708871C (en) | 2007-12-21 | 2017-11-21 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173 |
US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
EP3825329A1 (en) * | 2007-12-26 | 2021-05-26 | Xencor, Inc. | Fc variants with altered binding to fcrn |
AU2009205995B2 (en) | 2008-01-18 | 2014-04-03 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
EP2080770A1 (en) * | 2008-01-21 | 2009-07-22 | MorphoSys AG | Proteinaceous binding molecules comprising purification tags |
MX2010008578A (en) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity. |
CN102046195A (en) | 2008-04-02 | 2011-05-04 | 宏观基因有限公司 | HER2/neu-specific antibodies and methods of using same |
US8669349B2 (en) | 2008-04-02 | 2014-03-11 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
SI2275443T1 (en) | 2008-04-11 | 2016-03-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP2280997A2 (en) * | 2008-04-18 | 2011-02-09 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
AR077718A1 (en) * | 2008-07-15 | 2011-09-21 | Genentech Inc | METHODS TO TREAT AUTOIMMUNE DISEASES USING ANTI CD4 ANTIBODIES. PHARMACEUTICAL FORMULATION |
RU2581962C2 (en) | 2008-09-19 | 2016-04-20 | Медиммун Ллк | Targeted binding agents against dll4 and application thereof |
TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
JP5913980B2 (en) * | 2008-10-14 | 2016-05-11 | ジェネンテック, インコーポレイテッド | Immunoglobulin variants and uses thereof |
US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
ES2719496T3 (en) | 2008-11-12 | 2019-07-10 | Medimmune Llc | Antibody formulation |
SI2361085T2 (en) | 2008-11-22 | 2018-11-30 | F. Hoffmann-La Roche Ag | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
EP2373689A1 (en) | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
WO2010072740A2 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF |
WO2010078526A1 (en) | 2008-12-31 | 2010-07-08 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
BRPI1007005A2 (en) * | 2009-01-29 | 2016-03-22 | Medimmune Llc | isolated antibody, isolated nucleic acid n vector, isolated cell, isolated cell line, pharmaceutical composition, and use of an anti-il-6 antibody |
EP2403879A1 (en) | 2009-03-06 | 2012-01-11 | Kalobios Pharmaceuticals, Inc. | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 |
MX338098B (en) | 2009-03-09 | 2016-04-01 | Bioatla Llc | Mirac proteins. |
UA108349C2 (en) * | 2009-03-16 | 2015-04-27 | Сефалон Острейліа Пті Лтд | Humanized antibody with antitumor activity |
JP5787446B2 (en) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | Antibody constant region variants |
EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
WO2010111367A1 (en) | 2009-03-25 | 2010-09-30 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
MA33276B1 (en) | 2009-04-20 | 2012-05-02 | Oxford Biotherapeutics Ltd | Cadherine-17 antibodies |
US20120134984A1 (en) * | 2009-06-01 | 2012-05-31 | Olga Lubman | Molecules with extended half-lives and uses thereof |
BRPI1015234A2 (en) | 2009-06-22 | 2018-02-20 | Medimmune Llc | fc regions designed for site specific conjugation. |
JP5762408B2 (en) * | 2009-08-13 | 2015-08-12 | クルセル ホランド ベー ヴェー | Antibodies against human respiratory syncytial virus (RSV) and methods of use |
EP3381937A3 (en) | 2009-08-13 | 2018-10-31 | The Johns Hopkins University | Methods of modulating immune function |
WO2011022264A1 (en) | 2009-08-15 | 2011-02-24 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
JP2013502458A (en) | 2009-08-24 | 2013-01-24 | アムニクス オペレーティング インコーポレイテッド | Coagulation factor VII composition and methods of making and using the same |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
IN2012DN03025A (en) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
US20110189183A1 (en) | 2009-09-18 | 2011-08-04 | Robert Anthony Williamson | Antibodies against candida, collections thereof and methods of use |
WO2011037158A1 (en) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | Modified antibody constant regions |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
JP5898082B2 (en) | 2009-10-07 | 2016-04-06 | マクロジェニクス,インコーポレーテッド | Fc region-containing polypeptide exhibiting improved effector function by changing the degree of fucosylation and use thereof |
EP2470569A1 (en) | 2009-10-13 | 2012-07-04 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
DK2488554T3 (en) | 2009-10-14 | 2019-09-02 | Humanigen Inc | ANTIBODIES AGAINST EPHA3 |
WO2011050188A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Anti-hepsin antibodies and methods using same |
MX341084B (en) | 2009-11-02 | 2016-08-05 | Univ Washington | Therapeutic nuclease compositions and methods. |
AU2010315101B2 (en) | 2009-11-04 | 2016-01-28 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
WO2011054030A1 (en) | 2009-11-05 | 2011-05-12 | Cephalon Australia Pty Ltd | Treatment of cancer involving mutated kras or braf genes |
NZ598901A (en) | 2009-11-05 | 2014-08-29 | Genentech Inc | Methods and composition for secretion of heterologous polypeptides |
US8881354B2 (en) | 2009-11-16 | 2014-11-11 | Jtekt Corporation | Tool radius adjusting system for boring holder, tool radius adjusting method in machine tool, and machine tool |
EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
EP2516468B1 (en) | 2009-12-23 | 2016-03-02 | Synimmune GmbH | Anti-flt3 antibodies and methods of using the same |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
WO2011088215A2 (en) | 2010-01-13 | 2011-07-21 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
CA2789629A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Cd20 antibodies and uses thereof |
WO2011102845A1 (en) * | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
RU2012140447A (en) | 2010-02-23 | 2014-03-27 | Дженентек, Инк. | ANTIANGIOGENIC THERAPY FOR TREATMENT OF OVARIAN CANCER |
WO2011105129A1 (en) | 2010-02-25 | 2011-09-01 | 旭化成株式会社 | Copper oxide etchant and etching method using same |
JP5889181B2 (en) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | Antibody constant region variants |
ES2895480T3 (en) | 2010-03-04 | 2022-02-21 | Macrogenics Inc | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US8642557B2 (en) | 2010-03-12 | 2014-02-04 | Abbvie Biotherapeutics Inc. | CTLA4 proteins and their uses |
TWI667257B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
CA2797856C (en) | 2010-04-30 | 2018-09-18 | Alexion Pharmaceuticals, Inc. | Anti-c5a antibodies and methods for using the antibodies |
RU2604811C2 (en) | 2010-05-27 | 2016-12-10 | Мерк Шарп Энд Домэ Корп. | Method for preparing antibodies having improved properties |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
NZ701208A (en) | 2010-06-03 | 2016-05-27 | Genentech Inc | Immuno-pet imaging of antibodies and immunoconjugates and uses thereof |
NZ702485A (en) | 2010-06-03 | 2016-04-29 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
BR112012033119A2 (en) | 2010-06-22 | 2016-10-25 | Univ Colorado Regents | antibodies to complement component c3d fragment 3. |
EA027835B1 (en) | 2010-07-09 | 2017-09-29 | Круселл Холланд Б.В. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use thereof |
WO2012006635A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Processable single chain molecules and polypeptides made using same |
NZ604415A (en) | 2010-07-20 | 2014-10-31 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
AU2011280969A1 (en) | 2010-07-23 | 2013-02-07 | Trustees Of Boston University | Anti-Despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
HRP20230776T1 (en) | 2010-07-29 | 2023-10-27 | Buzzard Pharmaceuticals AB | Chimeric il-1 receptor type i antagonists |
JP5964300B2 (en) | 2010-08-02 | 2016-08-03 | マクロジェニクス,インコーポレーテッド | Covalently bonded diabody and its use |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
AU2011288412A1 (en) | 2010-08-13 | 2013-02-21 | Medimmune Limited | Monomeric polypeptides comprising variant Fc regions and methods of use |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
WO2012027723A1 (en) | 2010-08-27 | 2012-03-01 | Stem Centrx, Inc | Notum protein modulators and methods of use |
EP2611464B1 (en) | 2010-09-03 | 2018-04-25 | AbbVie Stemcentrx LLC | Novel modulators and methods of use |
EP2621954A1 (en) | 2010-10-01 | 2013-08-07 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
UA112062C2 (en) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | CD33-Binding Agent |
WO2012051111A2 (en) | 2010-10-13 | 2012-04-19 | Janssen Biotech, Inc. | Human oncostatin m antibodies and methods of use |
EP2635607B1 (en) | 2010-11-05 | 2019-09-04 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
TWI452135B (en) | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
KR101947356B1 (en) | 2010-11-23 | 2019-02-12 | 글락소 그룹 리미티드 | Antigen binding proteins to oncostatin m (osm) |
BR112013013003A2 (en) | 2010-11-24 | 2016-08-09 | Glaxo Group Ltd | antigen binding protein and pharmaceutical composition |
TWI654204B (en) | 2010-11-30 | 2019-03-21 | 中外製藥股份有限公司 | Antibody with calcium-dependent antigen binding ability |
SI2647707T1 (en) | 2010-11-30 | 2018-12-31 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
PE20140673A1 (en) | 2010-12-08 | 2014-06-14 | Stem Centrx Inc | NEW MODULATORS AND METHODS FOR THEIR USE |
MX2013007392A (en) | 2010-12-22 | 2013-11-01 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life. |
JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
US9447187B2 (en) | 2011-02-03 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
WO2012109285A2 (en) | 2011-02-08 | 2012-08-16 | Medimmune, Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
MX352889B (en) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Fcîriib-specific fc antibody. |
MX336740B (en) | 2011-03-29 | 2016-01-29 | Roche Glycart Ag | Antibody fc variants. |
BR112013026423A2 (en) | 2011-04-20 | 2016-11-29 | Roche Glycart Ag | method and constructs for blood-brain barrier ph pending passage |
JP6152090B2 (en) | 2011-04-21 | 2017-06-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | Compositions and methods for treating optic neuritis |
EP3449933A1 (en) | 2011-04-29 | 2019-03-06 | University of Washington | Therapeutic nuclease compositions and methods |
EA201391753A1 (en) | 2011-05-21 | 2014-08-29 | Макродженикс, Инк. | DOMAINS CONNECTING WITH DEIMMUNIZED SERUM AND THEIR APPLICATION TO INCREASE THE TIME OF HALF-DURATION |
EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
KR20140028013A (en) | 2011-05-25 | 2014-03-07 | 머크 샤프 앤드 돔 코포레이션 | Method for preparing fc-containing polypeptides having improved properties |
WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
WO2012170740A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
EP2717898B1 (en) | 2011-06-10 | 2018-12-19 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
LT2718320T (en) | 2011-06-10 | 2018-04-10 | Medimmune Limited | Anti-pseudomonas psl binding molecules and uses thereof |
ES2828482T3 (en) | 2011-06-13 | 2021-05-26 | Csl Ltd | Antibodies to g-csfr and their use |
EP3628327A1 (en) | 2011-06-24 | 2020-04-01 | The Regents of the University of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
EP2726508B1 (en) | 2011-06-28 | 2017-08-09 | Oxford BioTherapeutics Ltd | Antibodies to adp-ribosyl cyclase 2 |
CN103917563A (en) * | 2011-06-28 | 2014-07-09 | 英伊布里克斯有限责任公司 | Serpin fusion polypeptides and methods of use thereof |
RU2639526C2 (en) * | 2011-06-28 | 2017-12-21 | ИНХИБРКС ЭлЭлСи | Fusion polypeptide containing wap domain and their application methods |
US10400029B2 (en) * | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
UA117901C2 (en) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Antibody variants and uses thereof |
KR20140048276A (en) | 2011-07-15 | 2014-04-23 | 온코메드 파마슈티칼스, 인크. | Rspo binding agents and uses thereof |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
US20130022551A1 (en) | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
IL230564B2 (en) | 2011-07-22 | 2023-09-01 | Csl Ltd | Inhibitory anti-factor xii/xiia monoclonal antibodies, methods of producing the same, pharmaceutical compositions containing the same and medical uses |
CN103842380A (en) | 2011-07-27 | 2014-06-04 | 葛兰素集团有限公司 | Anti-VEGF single variable domains fused to Fc domains |
BR112014002173A2 (en) | 2011-07-29 | 2017-03-01 | Eleven Biotherapeutics Inc | purified proteins |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
UY34317A (en) | 2011-09-12 | 2013-02-28 | Genzyme Corp | T cell antireceptor antibody (alpha) / ß |
US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
US8858941B2 (en) | 2011-09-23 | 2014-10-14 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
EA035018B1 (en) | 2011-09-30 | 2020-04-17 | Тева Фармасьютикал Австралия Пти Лтд. | ANTIBODIES AGAINST TL1a AND USES THEREOF |
CA2850322C (en) | 2011-09-30 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule inducing immune response to target antigen |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
RU2014117505A (en) | 2011-09-30 | 2015-11-10 | Чугаи Сейяку Кабусики Кайся | ANTIGEN-BINDING MOLECULE FOR ACCELERATION OF REMOVAL OF ANTIGENS |
TW201326209A (en) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
JP6271251B2 (en) | 2011-10-05 | 2018-01-31 | 中外製薬株式会社 | An antigen-binding molecule that promotes elimination of an antigen containing a sugar chain receptor-binding domain from plasma |
PT2771022T (en) | 2011-10-11 | 2020-09-14 | Viela Bio Inc | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
KR102276161B1 (en) | 2011-10-25 | 2021-07-14 | 프로테나 바이오사이언시즈 리미티드 | Antibody formulations and methods |
CN104203982B (en) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | Polypeptide construct and application thereof |
US9221907B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Anti-GPR49 monoclonal antibodies |
WO2013067057A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
CN104053671A (en) | 2011-11-01 | 2014-09-17 | 生态学有限公司 | Antibodies and methods of treating cancer |
EP2773373B1 (en) | 2011-11-01 | 2018-08-22 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
MX358862B (en) | 2011-11-04 | 2018-09-06 | Zymeworks Inc | Stable heterodimeric antibody design with mutations in the fc domain. |
US9580509B2 (en) | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
BR112014011028B1 (en) | 2011-11-07 | 2021-03-02 | Medimmune, Llc | bispecific antibody, composition, and, use of composition |
US20140302028A1 (en) * | 2011-11-18 | 2014-10-09 | Merck Sharp & Dohme Corp. | Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding |
KR102080535B1 (en) | 2011-11-23 | 2020-02-24 | 메디뮨 엘엘씨 | Binding molecules specific for her3 and uses thereof |
CN104080909A (en) | 2011-11-30 | 2014-10-01 | 中外制药株式会社 | Drug containing carrier into cell for forming immune complex |
ES2784131T3 (en) | 2011-12-05 | 2020-09-22 | X Body Inc | PDGF receptor beta-binding polypeptides |
DK2794905T3 (en) | 2011-12-20 | 2020-07-06 | Medimmune Llc | MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY BASIC STRUCTURES |
CN104302665B (en) * | 2011-12-21 | 2019-04-23 | 安姆根有限公司 | And the variant Fc polypeptide of the combination enhancing of neonatal Fc receptor |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
WO2013096948A1 (en) | 2011-12-23 | 2013-06-27 | Lydon Nicholas B | Immunoglobulins and variants directed against pathogenic microbes |
KR102041412B1 (en) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | Derivatives of Immunglobulin Fc fragment |
WO2013106589A1 (en) | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
RS59670B1 (en) | 2012-01-12 | 2020-01-31 | Bioverativ Therapeutics Inc | Chimeric factor viii polypeptides and uses thereof |
EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
CN113527469A (en) * | 2012-02-09 | 2021-10-22 | 中外制药株式会社 | Fc region variants of antibodies |
WO2013122617A1 (en) | 2012-02-15 | 2013-08-22 | Amunix Operating Inc. | Factor viii compositions and methods of making and using same |
WO2013123457A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
CN104520324A (en) | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | DLL3 modulators and methods of use |
AU2013223087B2 (en) | 2012-02-24 | 2018-02-22 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via FcgammaRIIb |
BR112014024282A2 (en) | 2012-03-28 | 2017-08-08 | Sanofi Sa | bradykinin b1 receptor binding antibodies |
US10385395B2 (en) | 2012-04-11 | 2019-08-20 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
US9212227B2 (en) * | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
ES2746103T3 (en) * | 2012-04-30 | 2020-03-04 | Medimmune Llc | Molecules with reduced effector function and long half-lives, compositions and uses thereof |
CA2872856A1 (en) | 2012-05-07 | 2013-11-14 | Sanofi | Methods for preventing biofilm formation |
US20130336973A1 (en) | 2012-05-10 | 2013-12-19 | Zymeworks Inc. | Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
RU2743463C2 (en) | 2012-05-30 | 2021-02-18 | Чугаи Сейяку Кабусики Кайся | Antigen-binding molecule specific to target tissue |
DK2857419T3 (en) | 2012-05-30 | 2021-03-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule for the elimination of aggregated antigens |
JP2015520192A (en) | 2012-06-06 | 2015-07-16 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Binding agents that modulate the Hippo pathway and uses thereof |
JP2015521589A (en) | 2012-06-08 | 2015-07-30 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Procoagulant compounds |
WO2013185114A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
US9499634B2 (en) | 2012-06-25 | 2016-11-22 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
WO2014008480A2 (en) | 2012-07-06 | 2014-01-09 | Biogen Idec Ma Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
KR102329315B1 (en) | 2012-07-11 | 2021-11-19 | 바이오버라티브 테라퓨틱스 인크. | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
HRP20211641T1 (en) | 2012-07-13 | 2022-02-04 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
CA2880007C (en) | 2012-07-25 | 2021-12-28 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
EP2888279A1 (en) | 2012-08-22 | 2015-07-01 | Glaxo Group Limited | Anti lrp6 antibodies |
JP6774164B2 (en) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | Mouse FcγRII specific Fc antibody |
NZ705370A (en) | 2012-08-24 | 2018-06-29 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
KR20220110855A (en) | 2012-09-12 | 2022-08-09 | 젠자임 코포레이션 | Fc containing polypeptides with altered glycosylation and reduced effector function |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
EP2928483A4 (en) | 2012-12-04 | 2016-06-08 | Oncomed Pharm Inc | Immunotherapy with binding agents |
AU2013361275B2 (en) | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
EP2935332B1 (en) | 2012-12-21 | 2021-11-10 | MedImmune, LLC | Anti-h7cr antibodies |
AU2013372331A1 (en) | 2013-01-10 | 2015-07-23 | Genmab B.V. | Human IgG1 Fc region variants and uses thereof |
BR112015017619A2 (en) | 2013-01-24 | 2017-11-21 | Glaxosmithkline Ip Dev Ltd | liquid formulation, use of a formulation, and kit |
CN104902915B (en) | 2013-01-25 | 2018-07-06 | 夏尔人类遗传性治疗公司 | Treat the follistatin of Duchenne muscular dystrophy |
CA2899960C (en) | 2013-02-01 | 2022-05-03 | Transbio Ltd | Anti-cd83 antibodies and use thereof |
US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
EP4219552A3 (en) | 2013-02-07 | 2023-09-13 | CSL Ltd. | Il-11r binding proteins and uses thereof |
HRP20231183T1 (en) | 2013-02-15 | 2024-01-05 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
AU2014218730B2 (en) | 2013-02-22 | 2018-12-13 | Abbvie Stemcentrx Llc | Novel antibody conjugates and uses thereof |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
CA2901225C (en) | 2013-03-08 | 2023-09-19 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
SG11201506086SA (en) | 2013-03-11 | 2015-09-29 | Genzyme Corp | Site-specific antibody-drug conjugation through glycoengineering |
CA2903706C (en) | 2013-03-13 | 2024-01-23 | Eleven Biotherapeutics, Inc. | Chimeric cytokine formulations for ocular delivery |
US20140271641A1 (en) | 2013-03-14 | 2014-09-18 | University Of Guelph | Thrombospondin-1 polypeptides and methods of using same |
JP6676521B2 (en) | 2013-03-14 | 2020-04-08 | マクロジェニクス,インコーポレーテッド | Bispecific molecules, pharmaceutical compositions and uses thereof |
CA2899089C (en) | 2013-03-15 | 2021-10-26 | Biogen Ma Inc. | Factor ix polypeptide formulations |
WO2014144600A2 (en) | 2013-03-15 | 2014-09-18 | Viktor Roschke | Multivalent and monovalent multispecific complexes and their uses |
AU2014233503A1 (en) | 2013-03-15 | 2015-09-24 | Abbvie Biotechnology Ltd. | Anti-CD25 antibodies and their uses |
ES2699599T3 (en) | 2013-03-15 | 2019-02-11 | Abbvie Biotherapeutics Inc | Fc variants |
DK2970464T3 (en) | 2013-03-15 | 2020-08-03 | Glaxosmithkline Ip Dev Ltd | ANTI-LAYER-3 BINDING PROTEINS |
US9260527B2 (en) | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
DK3460054T3 (en) | 2013-03-15 | 2021-01-18 | Atyr Pharma Inc | Histidyl-tRNA-synthetase-Fc conjugates |
JP6404313B2 (en) | 2013-03-15 | 2018-10-10 | アムジエン・インコーポレーテツド | Heterodimeric bispecific antibody |
AU2014233478A1 (en) | 2013-03-15 | 2015-09-24 | Abbvie Biotechnology Ltd. | Anti-CD25 antibodies and their uses |
EP3783017A1 (en) | 2013-04-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
MX370377B (en) | 2013-04-29 | 2019-12-11 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b. |
KR102293064B1 (en) | 2013-05-20 | 2021-08-23 | 제넨테크, 인크. | Anti-transferrin receptor antibodies and methods of use |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
EP3875106A1 (en) | 2013-08-08 | 2021-09-08 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
UA116479C2 (en) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
MX2016001851A (en) | 2013-08-13 | 2016-05-16 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof. |
TW201722994A (en) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and uses thereof |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
MX2016002574A (en) | 2013-08-28 | 2016-06-14 | Stemcentrx Inc | Novel sez6 modulators and methods of use. |
RU2016111131A (en) | 2013-08-28 | 2017-10-03 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | METHODS FOR CONJUGATION OF SITE-SPECIFIC ANTIBODIES AND COMPOSITIONS |
WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
MX2016003292A (en) | 2013-09-13 | 2016-06-24 | Beigene Ltd | Anti-pd1 antibodies and their use as therapeutics and diagnostics. |
EP3733710A1 (en) | 2013-09-25 | 2020-11-04 | Amgen, Inc | Hetrodimeric v-c-fc-v-c antibody |
WO2015048330A2 (en) | 2013-09-25 | 2015-04-02 | Biogen Idec Ma Inc. | On-column viral inactivation methods |
DK3050896T3 (en) | 2013-09-27 | 2021-07-19 | Chugai Pharmaceutical Co Ltd | Process for the preparation of a polypeptide heteromultimer |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
WO2015051010A1 (en) | 2013-10-02 | 2015-04-09 | Medimmune, Llc | Neutralizing anti-influenza a antibodies and uses thereof |
RS61620B1 (en) | 2013-10-11 | 2021-04-29 | Oxford Bio Therapeutics Ltd | Conjugated antibodies against ly75 for the treatment of cancer |
EP3063275B1 (en) | 2013-10-31 | 2019-09-25 | Resolve Therapeutics, LLC | Therapeutic nuclease-albumin fusions and methods |
RU2016122041A (en) | 2013-11-06 | 2017-12-11 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | NEW ANTI-CLAUDIN ANTIBODIES AND WAYS OF THEIR APPLICATION |
US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
ES2909014T3 (en) * | 2013-11-26 | 2022-05-04 | Brigham & Womens Hospital Inc | Compositions and methods for modulating an immune response |
AU2014357354A1 (en) | 2013-12-02 | 2016-06-09 | Oncomed Pharmaceuticals, Inc. | Identification of predictive biomarkers associated with Wnt pathway inhibitors |
AU2014358191B2 (en) | 2013-12-04 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
US9546215B2 (en) | 2013-12-09 | 2017-01-17 | Allakos Inc. | Anti-Siglec-8 antibodies and methods of use thereof |
EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
MX368804B (en) | 2013-12-24 | 2019-10-17 | Univ Texas | FCRN ANTAGONISTS and METHODS OF USE. |
ES2927475T3 (en) | 2014-01-10 | 2022-11-07 | Bioverativ Therapeutics Inc | Factor VIII chimeric proteins and uses thereof |
WO2015123687A1 (en) | 2014-02-14 | 2015-08-20 | Centrose, Llc | Extracellular targeted drug conjugates |
EP3110446B1 (en) | 2014-02-28 | 2021-12-01 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
EP3116999B1 (en) | 2014-03-14 | 2021-09-15 | F. Hoffmann-La Roche AG | Methods and compositions for secretion of heterologous polypeptides |
US9738702B2 (en) * | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
MX2016012122A (en) | 2014-03-19 | 2017-09-01 | Genzyme Corp | Site-specific glycoengineering of targeting moieties. |
JP2017509336A (en) | 2014-03-20 | 2017-04-06 | ファーマサイクリックス エルエルシー | Mutations associated with phospholipase C gamma 2 and resistance |
CN106164094B (en) | 2014-03-21 | 2021-05-14 | X博迪公司 | Bispecific antigen binding polypeptides |
KR102352573B1 (en) | 2014-04-04 | 2022-01-18 | 바이오노믹스 인코포레이티드 | Humanized antibodies that bind lgr5 |
WO2015157238A2 (en) | 2014-04-08 | 2015-10-15 | Medimmune, Llc | Binding molecules specific for il-21 and uses thereof |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
EP3142700B1 (en) * | 2014-05-16 | 2021-03-03 | Medimmune, LLC | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
CA2949998A1 (en) | 2014-05-28 | 2015-12-03 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
CN106459191B (en) * | 2014-06-12 | 2021-12-10 | 豪夫迈·罗氏有限公司 | Methods of selecting antibodies with modified FcRn interactions |
EP3157945A4 (en) | 2014-06-20 | 2017-11-22 | F. Hoffmann-La Roche AG | Chagasin-based scaffold compositions, methods, and uses |
WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
JP6526189B2 (en) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | Anti-PD-L1 antibodies and their use for therapy and diagnosis |
CN113563462A (en) | 2014-07-15 | 2021-10-29 | 免疫医疗有限责任公司 | Neutralizing anti-influenza b antibodies and uses thereof |
ES2905301T3 (en) | 2014-07-22 | 2022-04-07 | Apollomics Inc | Anti-PD-1 antibodies |
KR102476226B1 (en) | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | Anti-pd-l1 antibodies |
US10457721B2 (en) | 2014-08-11 | 2019-10-29 | University Of Massachusetts | Anti-OSPA antibodies and methods of use |
KR102523914B1 (en) | 2014-09-03 | 2023-04-19 | 베링거잉겔하임인터내쇼날유한회사 | Compound targeting il-23a and tnf-alpha and uses thereof |
TW201617368A (en) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | Novel anti-MFI2 antibodies and methods of use |
AU2015323313B2 (en) | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
MX2017003897A (en) | 2014-09-26 | 2017-06-28 | Bayer Pharma AG | Stabilized adrenomedullin derivatives and use thereof. |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
BR112017006515A8 (en) | 2014-09-29 | 2018-02-27 | Univ Duke | bispecific molecules, compositions, method for treating or preventing HIV-1 infection in an individual with this need, and vector |
KR20230153495A (en) | 2014-10-01 | 2023-11-06 | 메디뮨 리미티드 | Antibodies to ticagrelor and methods of use |
CN113975406A (en) | 2014-10-09 | 2022-01-28 | 建新公司 | Glycoengineered antibody drug conjugates |
CN108064282A (en) | 2014-10-14 | 2018-05-22 | 哈洛齐梅公司 | Adenosine deaminase -2 (ADA2), its variant composition and use its method |
NZ731491A (en) | 2014-10-23 | 2021-12-24 | Kira Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
MX2017005481A (en) | 2014-10-29 | 2017-10-26 | Teva Pharmaceuticals Australia Pty Ltd | Interferon a2b variants. |
US20160130324A1 (en) | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
MX2017003478A (en) | 2014-11-05 | 2018-02-01 | Genentech Inc | Anti-fgfr2/3 antibodies and methods using same. |
KR20170076697A (en) * | 2014-11-06 | 2017-07-04 | 에프. 호프만-라 로슈 아게 | Fc-region variants with modified fcrn- and protein a-binding properties |
PL3218406T3 (en) | 2014-11-10 | 2021-10-04 | Medimmune Limited | Binding molecules specific for cd73 and uses thereof |
JP6847037B2 (en) | 2014-11-11 | 2021-03-24 | メディミューン リミテッド | Concomitant therapeutic agents containing anti-CD73 antibody and A2A receptor inhibitor and their use |
JP6779876B2 (en) | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | Anti-transferrin receptor antibody and how to use it |
JP6993228B2 (en) | 2014-11-19 | 2022-03-03 | ジェネンテック, インコーポレイテッド | Anti-transferrin receptor / anti-BACE1 multispecific antibody and usage |
KR20230125855A (en) | 2014-11-21 | 2023-08-29 | 브리스톨-마이어스 스큅 컴퍼니 | Antibodies against cd73 and uses thereof |
PT3221346T (en) | 2014-11-21 | 2020-10-23 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant regions |
US9382321B2 (en) | 2014-11-26 | 2016-07-05 | Adventis Health System/Sunbelt, Inc. | Effector-deficient anti-CD32A antibodies |
RU2017120039A (en) | 2014-12-10 | 2019-01-10 | Дженентек, Инк. | ANTIBODIES TO HEMATOENCEPHALIC BARRIER RECEPTORS AND METHODS OF APPLICATION |
KR101860280B1 (en) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
WO2016094962A1 (en) | 2014-12-19 | 2016-06-23 | Monash University | Il-21 antibodies |
CA2972048C (en) | 2014-12-22 | 2023-03-07 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
MY187045A (en) | 2014-12-23 | 2021-08-27 | Bristol Myers Squibb Co | Antibodies to tigit |
WO2016115345A1 (en) | 2015-01-14 | 2016-07-21 | The Brigham And Women's Hospital, | Treatment of cancer with anti-lap monoclonal antibodies |
CN107428818A (en) | 2015-01-29 | 2017-12-01 | 密西根州立大学校董会 | Hide polypeptide and application thereof |
KR20170110129A (en) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use |
WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
RU2730590C2 (en) | 2015-02-27 | 2020-08-24 | Чугаи Сейяку Кабусики Кайся | Composition for treating diseases associated with il-6 |
EP3268391B1 (en) | 2015-03-09 | 2021-08-11 | argenx BVBA | Methods of reducing serum levels of fc-containing agents using fcrn antagonsits |
FR3034420A1 (en) | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | ANTI-CD303 MONOCLONAL ANTIBODIES |
LT3277717T (en) | 2015-03-31 | 2021-08-10 | Medimmune Limited | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
CN108137687B (en) | 2015-05-29 | 2021-10-29 | 百时美施贵宝公司 | anti-OX 40 antibodies and uses thereof |
EA201792669A1 (en) | 2015-06-04 | 2018-06-29 | Оспедале Сан Раффаэле Срл | IGFBP3 AND ITS APPLICATION |
US20180169184A1 (en) | 2015-06-04 | 2018-06-21 | Ospedale San Raffaele Srl | Inhibitor of IGFBP3/TMEM219 Axis and Diabetes |
RU2732122C2 (en) | 2015-06-05 | 2020-09-11 | Дженентек, Инк. | Anti-tau protein antibodies and methods of using said antibodies |
TWI773646B (en) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | Lag-3-binding molecules and methods of use thereof |
AU2016278239B9 (en) | 2015-06-17 | 2022-08-11 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
KR20180021833A (en) | 2015-06-29 | 2018-03-05 | 더 락커펠러 유니버시티 | Antibodies to CD40 with enhanced agonist activity |
BR112018001255A2 (en) | 2015-07-23 | 2018-09-11 | Boehringer Ingelheim International Gmbh | il-23a-directed compound and b-cell activation factor (baff) and their uses |
DK3328419T3 (en) | 2015-07-30 | 2021-10-11 | Macrogenics Inc | PD-1 BINDING MOLECULES AND METHODS FOR USING IT |
CN108026582A (en) | 2015-07-31 | 2018-05-11 | 米迪缪尼有限公司 | Methods for treating hepcidin-mediated disorders |
AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
CN114605548A (en) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | anti-PD-1 antibodies and methods of use thereof |
EP3344654B1 (en) | 2015-09-02 | 2020-10-21 | Immutep S.A.S. | Anti-lag-3 antibodies |
TWI799366B (en) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | Cystine knot scaffold platform |
WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
TWI703158B (en) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | Antibodies that specifically bind to tl1a |
JP6967003B2 (en) | 2015-09-23 | 2021-11-17 | メレオ バイオファーマ 5 インコーポレイテッド | Methods and compositions for the treatment of cancer |
RU2022102624A (en) | 2015-10-01 | 2022-03-10 | Хит Байолоджикс, Инк. | COMPOSITIONS AND METHODS FOR CONNECTING TYPE I AND TYPE II EXTRACELLULAR DOMAIN AS HETEROLOGOUS CHIMERIC PROTEINS |
RU2731202C2 (en) | 2015-10-08 | 2020-08-31 | Макродженикс, Инк. | Combined therapy for cancer treatment |
KR101981943B1 (en) | 2015-10-12 | 2019-05-24 | 주식회사 에이프로젠케이아이씨 | Anti-CD43 antibodies and their use in the treatment of cancer |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
SG10202103712VA (en) | 2015-11-10 | 2021-05-28 | Medimmune Llc | Binding molecules specific for asct2 and uses thereof |
JP2019500327A (en) | 2015-11-30 | 2019-01-10 | アッヴィ・インコーポレイテッド | Anti-huLRRC15 antibody drug conjugate and method of use thereof |
JP2019501124A (en) | 2015-11-30 | 2019-01-17 | アッヴィ・インコーポレイテッド | Anti-huLRRC15 antibody drug conjugate and method of use thereof |
MX2018006477A (en) | 2015-12-02 | 2018-09-03 | Agenus Inc | Antibodies and methods of use thereof. |
TW202208440A (en) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | Bispecific Molecules Having Immunoreactivity with PD-1 and CTLA-4, and Methods of Use Thereof |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
WO2017115773A1 (en) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Method for promoting efficiency of purification of fc region-containing polypeptide |
KR20180093068A (en) | 2015-12-31 | 2018-08-20 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | PCSK9 antibody, an antigen-binding fragment thereof and a medical application thereof |
US20200270365A1 (en) | 2016-01-05 | 2020-08-27 | Jiangsu Hengrui Medicine Co., Ltd. | Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof |
RS63548B1 (en) | 2016-02-01 | 2022-09-30 | Bioverativ Therapeutics Inc | Optimized factor viii genes |
US20170233472A1 (en) | 2016-02-17 | 2017-08-17 | Macrogenics, Inc. | ROR1-Binding Molecules, and Methods of Use Thereof |
MA43588A (en) | 2016-03-04 | 2021-06-02 | Takeda Pharmaceuticals Co | RECOMBINANT FOLLISTATINE-FC FUSION PROTEINS AND THEIR USE IN THE TREATMENT OF DUCHENNE MUSCLE DYSTROPHY |
MX2018010672A (en) | 2016-03-04 | 2019-05-27 | Univ Rockefeller | Antibodies to cd40 with enhanced agonist activity. |
KR20230038311A (en) | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | Combination therapy with anti-cd73 antibodies |
SG10202007025PA (en) | 2016-03-14 | 2020-08-28 | Chugai Pharmaceutical Co Ltd | Cell injury inducing therapeutic drug for use in cancer therapy |
US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
CN108697799A (en) | 2016-03-22 | 2018-10-23 | 生态学有限公司 | The application of anti-LGR5 monoclonal antibodies |
IL262010B (en) | 2016-04-04 | 2022-09-01 | Bioverativ Usa Inc | Anti-complement factor bb antibodies and uses thereof |
MA45473A (en) | 2016-04-04 | 2019-02-13 | Shire Human Genetic Therapies | CONJUGATE C1 ESTERASE INHIBITOR AND ITS USES |
AU2017249435A1 (en) | 2016-04-15 | 2018-10-25 | Macrogenics, Inc. | Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
EP3454864A4 (en) | 2016-04-21 | 2021-01-13 | Abbvie Stemcentrx LLC | Novel anti-bmpr1b antibodies and methods of use |
KR102543118B1 (en) | 2016-05-27 | 2023-06-14 | 아게누스 인코포레이티드 | Anti-tim-3 antibodies and methods of use thereof |
CA3026880A1 (en) | 2016-06-08 | 2017-12-14 | Paul Foster | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
US20190169280A1 (en) | 2016-06-30 | 2019-06-06 | Prothena Biosciences Limited | Compositions for treating amyloidosis |
CA3029627A1 (en) | 2016-07-01 | 2018-01-04 | Resolve Therapeutics, Llc | Optimized binuclease fusions and methods |
NZ749997A (en) | 2016-07-05 | 2022-11-25 | Beigene Ltd | Combination of a pd-l antagonist and a raf inhibitor for treating cancer |
CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
WO2018013917A1 (en) | 2016-07-15 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
JP7241677B2 (en) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Anti-CD47 combination therapy |
CN110072887A (en) | 2016-08-02 | 2019-07-30 | 威特拉公司 | Engineered polypeptide and its application |
CN109689090B (en) | 2016-08-05 | 2023-12-26 | 免疫医疗有限责任公司 | anti-O2 antibodies and uses thereof |
WO2018025982A1 (en) | 2016-08-05 | 2018-02-08 | 中外製薬株式会社 | Composition for prophylaxis or treatment of il-8 related diseases |
US10538579B2 (en) | 2016-08-15 | 2020-01-21 | Board Of Regents, The University Of Texas System | Bispecific pertussis antibodies |
US20210332112A1 (en) * | 2016-08-15 | 2021-10-28 | Board Of Regents, The University Of Texas System | Stabilized pertussis antibodies with extended half-life |
DK3500299T3 (en) | 2016-08-19 | 2024-01-29 | Beigene Switzerland Gmbh | Combination of zanubrutinib with an anti-CD20 or an anti-PD-1 antibody for use in the treatment of cancer |
EP3509616A1 (en) | 2016-09-09 | 2019-07-17 | H. Hoffnabb-La Roche Ag | Selective peptide inhibitors of frizzled |
US20190270821A1 (en) | 2016-09-13 | 2019-09-05 | Humanigen, Inc. | Epha3 antibodies for the treatment of pulmonary fibrosis |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
SG11201903063UA (en) | 2016-10-19 | 2019-05-30 | Medimmune Llc | Anti-o1 antibodies and uses thereof |
TW202300515A (en) | 2016-10-20 | 2023-01-01 | 法商賽諾菲公司 | Anti-chikv antibodies and uses thereof |
JP7265984B2 (en) | 2016-10-21 | 2023-04-27 | アディマブ, エルエルシー | Anti-respiratory syncytial virus antibodies and methods of their production and use |
AU2017345759A1 (en) | 2016-10-21 | 2019-05-23 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
EP3529270A2 (en) | 2016-10-21 | 2019-08-28 | Adimab, LLC | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
TWI788307B (en) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
AU2017359467A1 (en) | 2016-11-09 | 2019-05-02 | Agenus Inc. | Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof |
AU2017366709A1 (en) | 2016-12-02 | 2019-07-18 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
AU2017368328A1 (en) | 2016-12-02 | 2019-07-18 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
TWI789371B (en) | 2016-12-07 | 2023-01-11 | 美商建南德克公司 | Anti-tau antibodies and methods of use |
CN110290801B (en) | 2016-12-07 | 2024-01-26 | 基因泰克公司 | anti-TAU antibodies and methods of use |
ES2963226T3 (en) | 2016-12-07 | 2024-03-26 | Agenus Inc | ANTI-CTLA-4 antibodies and methods of their use |
PE20190921A1 (en) | 2016-12-07 | 2019-06-26 | Agenus Inc | ANTIBODIES AND METHODS OF THEIR USE |
EA201991514A1 (en) | 2016-12-21 | 2019-12-30 | Сефалон, Инк. | ANTIBODIES THAT SPECIALLY CONTACT THE IL-15 AND THEIR APPLICATION |
MD3558391T2 (en) | 2016-12-23 | 2022-05-31 | Immunogen Inc | Immunoconjugates targeting ADAM9 and methods of use thereof |
CN110167591B (en) | 2016-12-23 | 2023-09-26 | 宏观基因有限公司 | ADAM9 binding molecules and methods of using the same |
TW201825515A (en) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Met antibodies and immunoconjugates and uses thereof |
EP3565888A1 (en) | 2017-01-06 | 2019-11-13 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
WO2018129336A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
AU2018213194B2 (en) | 2017-01-25 | 2023-01-12 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes |
CN110225924B (en) | 2017-01-25 | 2024-04-02 | 免疫医疗有限公司 | Relaxin fusion polypeptides and uses thereof |
US11203636B2 (en) | 2017-02-01 | 2021-12-21 | Yale University | Treatment of existing left ventricular heart failure |
JP7304288B2 (en) | 2017-02-17 | 2023-07-06 | サノフイ | Multispecific binding molecules with specificity for dystroglycan and laminin-2 |
US10626169B2 (en) | 2017-02-17 | 2020-04-21 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
PE20191551A1 (en) | 2017-02-17 | 2019-10-24 | Denali Therapeutics Inc | DESIGNED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
BR112019017628A2 (en) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | cd137 x ta binding molecule, pharmaceutical compositions, use of cd137 x ta binding molecule, cd137 binding molecule, use of cd137 binding molecule, her2 / neu binding molecule, use of her2 binding molecule / neu, and use of a composition |
EP3585410B9 (en) | 2017-02-27 | 2023-10-04 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
EP3596125A1 (en) | 2017-03-16 | 2020-01-22 | Medimmune Limited | Anti-par2 antibodies and uses thereof |
UY37651A (en) | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | IL-1R-I UNION POLYPEPTIDE |
TWI788340B (en) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | Anti-icos agonist antibodies and uses thereof |
MA50956A (en) | 2017-04-13 | 2020-10-14 | Agenus Inc | ANTI-CD137 ANTIBODIES AND RELATED METHODS OF USE |
US20200033347A1 (en) | 2017-04-18 | 2020-01-30 | Universite Libre De Bruxelles | Biomarkers And Targets For Proliferative Diseases |
CN110536694A (en) | 2017-04-20 | 2019-12-03 | Atyr 医药公司 | For treating pulmonary inflammatory composition and method |
WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
ES2952961T3 (en) | 2017-05-01 | 2023-11-07 | Agenus Inc | Anti-TIGIT antibodies and methods of their use |
EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils |
KR20200016232A (en) | 2017-05-05 | 2020-02-14 | 알라코스 인크. | Methods and compositions for treating allergic eye diseases |
BR112019023409A2 (en) | 2017-05-10 | 2020-06-16 | Iovance Biotherapeutics, Inc. | METHODS FOR TREATING CANCER IN A PATIENT AND A HEMATOLOGICAL MALIGNITY, FOR EXPANDING TUMOR INFILTRANT LYMPHOCYTES, PERIPHERAL BLOOD LYMPHOCYTES AND INFILTRANT SPRAY LYMPHOCYTES, PROCEDURE FOR THE PREPARATION OF A POPULATION IN THE MANUFACTURE OF A POPULATION OF TUMOR INFILTRANT LYMPHOCYTES. |
AU2018266893A1 (en) | 2017-05-12 | 2019-12-05 | Takeda Pharmaceutical Company Limited | Recombinant follistatin-Fc fusion proteins and use in treating Duchenne muscular dystrophy |
JOP20190271A1 (en) * | 2017-05-24 | 2019-11-21 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use for immune related disorders |
US20200299400A1 (en) | 2017-05-25 | 2020-09-24 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | Immunotherapy for hepatocellular carcinoma |
PT3658184T (en) | 2017-07-27 | 2023-11-29 | Alexion Pharma Inc | High concentration anti-c5 antibody formulations |
AU2018313921A1 (en) | 2017-08-09 | 2020-03-12 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
BR112020003670A2 (en) | 2017-08-22 | 2020-09-01 | Sanabio, Llc | soluble interferon receptors and their uses |
MX2020002076A (en) | 2017-08-25 | 2020-03-24 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof. |
JP7039694B2 (en) | 2017-10-31 | 2022-03-22 | スターテン・バイオテクノロジー・ベー・フェー | Anti-APOC3 antibody and how to use it |
US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
JP2021503885A (en) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood |
CN111801334B (en) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | Treatment of indolent or invasive B-cell lymphomas using combinations comprising BTK inhibitors |
PL3717011T3 (en) | 2017-11-29 | 2023-03-27 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
BR112020011483A2 (en) | 2017-12-08 | 2020-11-24 | Argenx Bvba | use of fcrn antagonists to treat generalized myasthenia gravis |
AU2018385409A1 (en) | 2017-12-12 | 2020-07-02 | Macrogenics Inc. | Bispecific CD 16-binding molecules and their use in the treatment of disease |
EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
US20210369775A1 (en) | 2017-12-15 | 2021-12-02 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
CN111788227A (en) | 2017-12-27 | 2020-10-16 | 百时美施贵宝公司 | anti-CD 40 antibodies and uses thereof |
FR3076294B1 (en) | 2017-12-29 | 2022-01-28 | Lab Francais Du Fractionnement | METHOD FOR PURIFYING ANTIBODIES FROM RAW MILK |
AU2019205936B2 (en) | 2018-01-05 | 2022-09-15 | Novo Nordisk A/S | Methods for treating IL-6 mediated inflammation without immunosuppression |
US11338020B2 (en) | 2018-01-09 | 2022-05-24 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
CA3088199A1 (en) | 2018-01-12 | 2019-07-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
AU2019215063A1 (en) | 2018-02-01 | 2020-09-03 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing Factor VIII |
EP3752600A1 (en) | 2018-02-13 | 2020-12-23 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
EP3752195A4 (en) | 2018-02-14 | 2021-11-17 | Viela Bio, Inc. | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
JP7337079B2 (en) | 2018-02-15 | 2023-09-01 | マクロジェニクス,インコーポレーテッド | Mutant CD3 binding domains and their use in combination therapy for the treatment of disease |
CA3091801A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
MX2020009296A (en) | 2018-03-15 | 2020-11-13 | Chugai Pharmaceutical Co Ltd | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use. |
CA3094174A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
KR20200133376A (en) * | 2018-03-21 | 2020-11-27 | 알렉소 온콜로지 인크. | Antibodies to signal-regulatory protein alpha and methods of use |
AU2019237215B2 (en) | 2018-03-23 | 2023-11-02 | Université Libre de Bruxelles | Wnt signaling agonist molecules |
AU2019244478A1 (en) | 2018-03-28 | 2020-11-12 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
MX2020009975A (en) | 2018-03-28 | 2020-10-12 | Bristol Myers Squibb Co | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use. |
CA3100007A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
SG11202011309SA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable interleukin 12 polypeptides and methods of use thereof |
AU2019268410A1 (en) | 2018-05-16 | 2020-12-17 | Csl Limited | Soluble complement receptor type 1 variants and uses thereof |
TW202015723A (en) | 2018-05-18 | 2020-05-01 | 美商百歐維拉提夫治療公司 | Methods of treating hemophilia a |
EP3800999A4 (en) | 2018-06-04 | 2022-06-01 | Biogen MA Inc. | Anti-vla-4 antibodies having reduced effector function |
TW202016151A (en) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | Multi-specific binding proteins for cancer treatment |
GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
AU2019287623A1 (en) | 2018-06-15 | 2021-01-07 | Amyl Therapeutics Srl | General amyloid interaction motif (GAIM) |
MX2020013466A (en) | 2018-06-26 | 2021-04-19 | Immunogen Inc | Immunoconjugates targeting adam9 and methods of use thereof. |
CN112601517A (en) | 2018-07-03 | 2021-04-02 | 百时美施贵宝公司 | FGF-21 formulations |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
JP7319348B2 (en) | 2018-07-19 | 2023-08-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Bispecific anti-BCMA x anti-CD3 antibodies and their uses |
CN113227385A (en) | 2018-08-09 | 2021-08-06 | 比奥维拉迪维治疗股份有限公司 | Nucleic acid molecules and their use for non-viral gene therapy |
US20210379153A1 (en) | 2018-08-29 | 2021-12-09 | Shattuck Labs, Inc. | Combination therapies comprising sirp alpha-based chimeric proteins |
CA3108951A1 (en) * | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
US11672826B2 (en) | 2018-08-30 | 2023-06-13 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
AU2019328290A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
TW202031273A (en) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | Treatment of nsclc patients refractory for anti-pd-1 antibody |
US20220119782A1 (en) * | 2018-08-31 | 2022-04-21 | Yale University | ENPP1 Polypeptides and Methods of Using Same |
WO2020069398A1 (en) | 2018-09-27 | 2020-04-02 | Akrevia Therapeutics Inc. | Masked cytokine polypeptides |
JP2022504287A (en) | 2018-10-03 | 2022-01-13 | スターテン・バイオテクノロジー・ベー・フェー | Antibodies specific for human and cynomolgus monkey APOC3, and methods of their use |
TW202029980A (en) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof |
EP3889179A4 (en) | 2018-11-01 | 2022-10-12 | Shandong New Time Pharmaceutical Co., Ltd. | Bispecific antibody and use thereof |
CN112969469A (en) | 2018-11-05 | 2021-06-15 | 艾欧凡斯生物治疗公司 | Treatment of anti-PD-1 antibody refractory NSCLC patients |
WO2020097627A1 (en) | 2018-11-09 | 2020-05-14 | University Of Massachusetts | Anti-cfae antibodies and methods of use |
SG11202104969RA (en) | 2018-11-16 | 2021-06-29 | Bristol Myers Squibb Co | Anti-nkg2a antibodies and uses thereof |
CN113348177A (en) | 2018-11-28 | 2021-09-03 | 百时美施贵宝公司 | Antibodies comprising modified heavy chain constant regions |
US20220048981A1 (en) | 2018-12-05 | 2022-02-17 | Bica Therapeutics Inc. | Modified product of fc domain of antibody |
WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
WO2020115283A1 (en) | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
WO2020115281A1 (en) | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Proteinaceous molecules binding factor ixa and factor x |
CN113453757A (en) | 2018-12-21 | 2021-09-28 | 科马布有限公司 | FIXaxFX bispecific antibodies with a common light chain |
WO2020139920A2 (en) | 2018-12-26 | 2020-07-02 | City Of Hope | Activatable masked anti-ctla4 binding proteins |
JP2022516505A (en) | 2018-12-28 | 2022-02-28 | スパークス・セラピューティクス・インコーポレイテッド | Claudin 18.2 specific binding molecule, composition and method thereof for the treatment of cancer and other diseases. |
BR112021013096A2 (en) | 2019-01-04 | 2022-04-19 | Resolve Therapeutics, Llc | TREATMENT OF SJÖGREN'S DISEASE WITH NUCLEASE FUSION PROTEINS |
AU2020211728A1 (en) | 2019-01-23 | 2021-08-12 | Encefa | CD31 competitors and uses thereof |
EP3930847B1 (en) | 2019-02-26 | 2024-02-14 | Inspirna, Inc. | High-affinity anti-mertk antibodies and uses thereof |
CN113840842A (en) | 2019-02-26 | 2021-12-24 | 詹森生物科技公司 | Combination therapy and patient stratification with bispecific anti-EGFR/c-Met antibodies |
AU2020233284A1 (en) | 2019-03-01 | 2021-09-16 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2020178638A1 (en) | 2019-03-05 | 2020-09-10 | Prothena Biosciences Limited | Methods of treating al amyloidosis |
CN113613676A (en) | 2019-03-19 | 2021-11-05 | 中外制药株式会社 | Antigen binding molecule comprising antigen binding domain whose binding activity to antigen is changed by MTA and library for obtaining the same |
EP3947458A1 (en) | 2019-04-03 | 2022-02-09 | Genzyme Corporation | Anti-alpha beta tcr binding polypeptides with reduced fragmentation |
GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
EP3962942A1 (en) | 2019-05-01 | 2022-03-09 | Novo Nordisk A/S | Anti-il-6 antibody formulation |
MX2021013766A (en) | 2019-05-14 | 2022-02-21 | Werewolf Therapeutics Inc | Separation moieties and methods and use thereof. |
US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
AU2020286968A1 (en) | 2019-06-07 | 2021-11-25 | Argenx Bvba | Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration |
MX2021015045A (en) | 2019-06-07 | 2022-03-17 | Amgen Inc | Bispecific binding constructs. |
JP2022537134A (en) | 2019-06-10 | 2022-08-24 | 武田薬品工業株式会社 | Combination therapy using CD38 antibody |
CN114174326A (en) | 2019-06-18 | 2022-03-11 | 拜耳公司 | Long-term stable adrenomedullin analogues and uses thereof |
AU2020294797A1 (en) | 2019-06-21 | 2021-12-23 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
WO2021021615A1 (en) | 2019-07-26 | 2021-02-04 | Shire Human Genetic Therapies, Inc. | Recombinant heme oxygenase-1 (ho-1) for the treatment of sickle cell disease |
CN114502593A (en) | 2019-08-06 | 2022-05-13 | 葛兰素史密斯克莱知识产权发展有限公司 | Biopharmaceutical compositions and related methods |
EP4013506A1 (en) | 2019-08-12 | 2022-06-22 | Aptevo Research and Development LLC | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
JP2022544785A (en) | 2019-08-13 | 2022-10-21 | エルピス・バイオファーマシューティカルズ | Modified interleukin-2 receptor beta agonist |
TW202122420A (en) | 2019-08-30 | 2021-06-16 | 美商艾吉納斯公司 | Anti-cd96 antibodies and methods of use thereof |
KR20220097891A (en) | 2019-09-30 | 2022-07-08 | 바이오버라티브 테라퓨틱스 인크. | Lentiviral vector formulation |
BR112022008629A2 (en) | 2019-11-15 | 2022-07-19 | Enthera S R L | ISOLATED ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF, ISOLATED POLYNUCLEOTIDE, VECTOR, ISOLATED CELL, PHARMACEUTICAL COMPOSITION, USE THEREOF AND METHOD FOR INHIBITING IGFBP3 BINDING TO THE TMEM219 RECEPTOR |
US20230039165A1 (en) | 2019-11-21 | 2023-02-09 | Enthera S.R.L. | Igfbp3 antibodies and therapeutic uses thereof |
WO2021105389A1 (en) | 2019-11-29 | 2021-06-03 | Kymab Limited | Treatment for physiological iron overload |
CN114867532A (en) | 2019-12-18 | 2022-08-05 | 豪夫迈·罗氏有限公司 | Bispecific anti-CCL 2 antibodies |
CA3163172A1 (en) | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
EP4100426A1 (en) | 2020-02-06 | 2022-12-14 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
EP3868396A1 (en) | 2020-02-20 | 2021-08-25 | Enthera S.R.L. | Inhibitors and uses thereof |
AR121462A1 (en) | 2020-02-28 | 2022-06-08 | Genzyme Corp | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION |
US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
US20230174626A1 (en) | 2020-03-27 | 2023-06-08 | Glaxosmithkline Biologicals Sa | Antibodies |
WO2021202463A1 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Anti-rsv antibodies |
AR121881A1 (en) | 2020-04-20 | 2022-07-20 | Genzyme Corp | HUMANIZED ANTI-FACTOR BB ANTIBODIES OF COMPLEMENT AND THEIR USES |
BR112022021450A2 (en) | 2020-04-24 | 2022-12-27 | Millennium Pharm Inc | CD19 OR LEADING FRAGMENT, METHOD OF TREATMENT OF A CANCER, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID, VECTOR AND, ISOLATED CELL |
US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
IL297977A (en) | 2020-05-17 | 2023-01-01 | Astrazeneca Uk Ltd | Sars-cov-2 antibodies and methods of selecting and using the same |
CN115803091A (en) | 2020-05-22 | 2023-03-14 | 福迈康股份公司 | ACE2-FC fusion protein and application thereof |
EP4161969A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Bispecific binding constructs |
EP4166574A1 (en) | 2020-06-10 | 2023-04-19 | Bica Therapeutics Inc. | Fusion protein containing erythropoietin polypeptide |
AU2021290997C1 (en) | 2020-06-17 | 2024-01-04 | Medimmune Limited | Heterodimeric relaxin fusions and uses thereof |
JP2023532266A (en) | 2020-06-23 | 2023-07-27 | ジアンスー カニョン ファーマシューティカル カンパニー リミテッド | Anti-CD38 antibody and use thereof |
KR20230023803A (en) * | 2020-06-23 | 2023-02-17 | 매든 어드바이저스 엘엘씨 | Anti-CCR5 monoclonal antibody-based compositions and methods |
EP4171614A1 (en) | 2020-06-29 | 2023-05-03 | Resolve Therapeutics, LLC | Treatment of sjogren's syndrome with nuclease fusion proteins |
EP4175650A1 (en) | 2020-07-06 | 2023-05-10 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
AR122933A1 (en) | 2020-07-10 | 2022-10-19 | Novo Nordisk As | METHODS TO TREAT CARDIOVASCULAR DISEASE |
EP4193153A1 (en) | 2020-08-06 | 2023-06-14 | Bioverativ USA Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
CA3190280A1 (en) | 2020-08-10 | 2022-02-17 | Astrazeneca Uk Limited | Sars-cov-2 antibodies for treatment and prevention of covid-19 |
WO2022040345A1 (en) | 2020-08-18 | 2022-02-24 | Cephalon, Inc. | Anti-par-2 antibodies and methods of use thereof |
KR20230060514A (en) | 2020-09-01 | 2023-05-04 | 다케다 야쿠힌 고교 가부시키가이샤 | Interleukin-2 muteins and uses thereof |
CR20230146A (en) | 2020-09-11 | 2023-06-07 | Medimmune Ltd | THERAPEUTIC B7-H4 BINDING MOLECULES |
DE102020125457A1 (en) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts presented by HLA-A*02 molecules for use in immunotherapy against various types of cancer |
DE102020125465A1 (en) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts presented by non-HLA-A*02 molecules for use in immunotherapy against various types of cancer |
TW202229312A (en) | 2020-09-29 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers |
EP4225330A1 (en) | 2020-10-06 | 2023-08-16 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
AU2021360889A1 (en) * | 2020-10-14 | 2023-06-15 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
EP4204091A2 (en) | 2020-10-29 | 2023-07-05 | Formycon AG | Ace2 fusion proteins and uses thereof |
CA3202233A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic BioPharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
JP2023551907A (en) | 2020-12-01 | 2023-12-13 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Tumor-associated antigens and CD3 binding proteins, related compositions, and methods |
JP2023553384A (en) | 2020-12-03 | 2023-12-21 | アムジエン・インコーポレーテツド | Immunoglobulin constructs with multiple binding domains |
CA3201560A1 (en) * | 2020-12-08 | 2022-06-16 | David Campbell | Half-life extending compositions and methods |
CA3201588A1 (en) | 2020-12-09 | 2022-06-16 | David Campbell | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
CA3202483A1 (en) | 2020-12-17 | 2022-06-23 | Maria Fardis | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
JP2024500403A (en) | 2020-12-17 | 2024-01-09 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of cancer with tumor-infiltrating lymphocytes |
AU2021399453A1 (en) | 2020-12-18 | 2023-07-27 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory syncytial virus-specific binding molecule |
US20240110152A1 (en) | 2020-12-31 | 2024-04-04 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
TW202241925A (en) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | Peptides displayed by hla for use in immunotherapy against different types of cancers |
AU2022211410A1 (en) | 2021-01-22 | 2023-08-10 | Elpis Biopharmaceuticals | Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2 |
EP4284919A1 (en) | 2021-01-29 | 2023-12-06 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
CN116917325A (en) | 2021-03-01 | 2023-10-20 | 西里欧发展公司 | Combination of masked CTLA4 and PD1/PDL1 antibodies for the treatment of cancer |
TW202317612A (en) | 2021-03-01 | 2023-05-01 | 美商艾希利歐發展股份有限公司 | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
AU2022230745A1 (en) | 2021-03-03 | 2023-08-17 | Formycon Ag | Formulations of ace2 fc fusion proteins |
CA3210755A1 (en) | 2021-03-05 | 2022-09-09 | Kenneth ONIMUS | Tumor storage and cell culture compositions |
CA3212439A1 (en) | 2021-03-19 | 2022-09-22 | Michelle SIMPSON-ABELSON | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
TW202305118A (en) | 2021-03-23 | 2023-02-01 | 美商艾歐凡斯生物治療公司 | Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
EP4314253A2 (en) | 2021-03-25 | 2024-02-07 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
AU2022251923A1 (en) | 2021-03-31 | 2023-11-16 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
WO2022212645A1 (en) | 2021-03-31 | 2022-10-06 | Bioverativ Usa Inc. | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
WO2022207785A1 (en) | 2021-03-31 | 2022-10-06 | Kymab Limited | Antibodies to gfral |
EP4320149A1 (en) | 2021-04-09 | 2024-02-14 | Takeda Pharmaceutical Company Limited | Antibodies targeting complement factor d and uses therof |
KR20240037185A (en) | 2021-04-19 | 2024-03-21 | 이오반스 바이오테라퓨틱스, 인크. | Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy |
US20230018888A1 (en) | 2021-04-26 | 2023-01-19 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
WO2022232044A2 (en) | 2021-04-26 | 2022-11-03 | Millennium Pharmaceuticals, Inc. | Anti-clec12a antibodies and uses thereof |
EP4340850A1 (en) | 2021-05-17 | 2024-03-27 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
CA3220227A1 (en) | 2021-05-28 | 2022-12-01 | Matthew Bruce | Combination therapies for treating cancer |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
IL309349A (en) | 2021-06-14 | 2024-02-01 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
AU2022295067A1 (en) | 2021-06-18 | 2023-12-21 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
WO2022271867A1 (en) | 2021-06-23 | 2022-12-29 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
WO2023004074A2 (en) | 2021-07-22 | 2023-01-26 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
CA3226942A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
CA3227515A1 (en) | 2021-08-03 | 2023-02-09 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions and stable isotope labeling peptide mapping method |
CA3229251A1 (en) * | 2021-08-16 | 2023-02-23 | Aaron RING | Interleukin-12 variants and methods of use |
CA3227716A1 (en) | 2021-08-20 | 2023-02-23 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
AU2022332285A1 (en) | 2021-08-23 | 2024-02-15 | Immunitas Therapeutics, Inc. | Anti-cd161 antibodies and uses thereof |
TW202323289A (en) | 2021-08-31 | 2023-06-16 | 日商大正製藥股份有限公司 | Anti-growth hormone antibody |
WO2023039488A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
CA3232700A1 (en) | 2021-09-24 | 2023-03-30 | Rafael CUBAS | Expansion processes and agents for tumor infiltrating lymphocytes |
WO2023056362A1 (en) | 2021-09-30 | 2023-04-06 | Seagen Inc. | B7-h4 antibody-drug conjugates for the treatment of cancer |
WO2023057893A1 (en) | 2021-10-05 | 2023-04-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapies for treating cancer |
TW202330612A (en) | 2021-10-20 | 2023-08-01 | 日商武田藥品工業股份有限公司 | Compositions targeting bcma and methods of use thereof |
US20230187042A1 (en) | 2021-10-27 | 2023-06-15 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
TW202342095A (en) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | Composition for treatment and prevention of covid-19 |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023091968A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
WO2023094507A1 (en) | 2021-11-24 | 2023-06-01 | Formycon Ag | Improved ace2 fusion proteins |
WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
WO2023111112A1 (en) | 2021-12-15 | 2023-06-22 | Medimmune Limited | Treatment using heterodimeric relaxin fusions |
WO2023114951A1 (en) | 2021-12-17 | 2023-06-22 | Viiv Healthcare Company | Combination therapies for hiv infections and uses thereof |
WO2023139107A1 (en) | 2022-01-18 | 2023-07-27 | argenx BV | Galectin-10 antibodies |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
TW202348252A (en) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | Combination therapies for treatment of cancer with therapeutic binding molecules |
US20230303719A1 (en) | 2022-03-03 | 2023-09-28 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023212304A1 (en) | 2022-04-29 | 2023-11-02 | 23Andme, Inc. | Antigen binding proteins |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
KR20230156844A (en) | 2022-05-02 | 2023-11-14 | 노보 노르디스크 에이/에스 | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutabeous administration |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
WO2023220597A1 (en) | 2022-05-10 | 2023-11-16 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta reduced-binding agonist |
WO2023245048A1 (en) | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
WO2023242371A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Ph-dependent hsa-binding molecules and methods of use |
WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
WO2024015830A1 (en) | 2022-07-12 | 2024-01-18 | Cytomx Therapeutics, Inc. | Epcam immunoconjugates and uses thereof |
US20240034780A1 (en) | 2022-07-22 | 2024-02-01 | Flagship Pioneering Innovations Vi, Llc | Antigen Binding Molecules Targeting Thymic Stromal Lymphopoietin (TSLP) |
WO2024026386A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibody formulations |
WO2024026395A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
US20240052051A1 (en) | 2022-07-29 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024042112A1 (en) | 2022-08-25 | 2024-02-29 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins and uses thereof |
WO2024050421A2 (en) | 2022-08-30 | 2024-03-07 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting programmed cell death protein 1 (pd-1) |
US20240101691A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043713A1 (en) * | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
Family Cites Families (169)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
ATE37983T1 (en) | 1982-04-22 | 1988-11-15 | Ici Plc | DELAYED RELEASE AGENT. |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
JP2532858B2 (en) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | Transformed myeloma cell line |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988007089A1 (en) * | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
JP3095168B2 (en) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | Antibodies with domain-denaturing constants |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
CA1340288C (en) | 1988-09-02 | 1998-12-29 | Robert Charles Ladner | Generation and selection of novel binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
KR900005995A (en) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | Modified Interleukin-2 and Method of Making the Same |
JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
JP2571874B2 (en) | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | Protein microsphere composition |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
WO1992005793A1 (en) | 1990-10-05 | 1992-04-16 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
DE69128253T2 (en) | 1990-10-29 | 1998-06-18 | Chiron Corp | SPECIFIC ANTIBODIES, METHOD FOR THEIR PRODUCTION AND THEIR USE |
DE69129154T2 (en) | 1990-12-03 | 1998-08-20 | Genentech Inc | METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES |
ES2096749T3 (en) | 1990-12-14 | 1997-03-16 | Cell Genesys Inc | CHEMICAL CHAINS FOR SIGNAL TRANSDUCTION ROADS ASSOCIATED WITH A RECEIVER. |
DK0503648T3 (en) * | 1991-03-12 | 2000-10-30 | Biogen Inc | CD2 binding domain of lymphocyte function-associated antigen 3 |
IE921169A1 (en) | 1991-04-10 | 1992-10-21 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
EP0582595A1 (en) | 1991-04-26 | 1994-02-16 | Surface Active Limited | Novel antibodies, and methods for their use |
CA2109528A1 (en) | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
DK0584279T3 (en) | 1991-05-14 | 2001-06-11 | Immune Response Corp Inc | Targeted delivery of genes encoding immunogenic proteins |
DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
ATE195656T1 (en) | 1991-06-05 | 2000-09-15 | Univ Connecticut | TARGETED RELEASE OF GENES ENCODING SECRETORY PROTEINS |
WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ATE463573T1 (en) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES |
US20020102257A1 (en) | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
ES2193143T3 (en) | 1992-03-05 | 2003-11-01 | Univ Texas | USE OF IMMUNOCONJUGADOS FOR THE DIAGNOSIS AND / OR THERAPY OF VASCULARIZA TUMORS. |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
AU3940293A (en) | 1992-04-03 | 1993-11-08 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
CA2118508A1 (en) * | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
AU658072B2 (en) | 1992-06-09 | 1995-03-30 | Hoppe Ag | Latch and lockset system |
EP0749475A4 (en) | 1992-08-26 | 1997-05-07 | Harvard College | Use of the cytokine ip-10 as an anti-tumor agent |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
ATE200625T1 (en) | 1992-10-09 | 2001-05-15 | Advanced Tissue Sciences Inc | LIVER RESERVE CELLS |
CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
EP1262564A3 (en) | 1993-01-07 | 2004-03-31 | Sequenom, Inc. | Dna sequencing by mass spectrometry |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
EP1231268B1 (en) | 1994-01-31 | 2005-07-27 | Trustees Of Boston University | Polyclonal antibody libraries |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
MX9700764A (en) | 1994-07-29 | 1997-05-31 | Smithkline Beecham Plc | Novel compounds. |
DE69630514D1 (en) | 1995-01-05 | 2003-12-04 | Univ Michigan | SURFACE-MODIFIED NANOPARTICLES AND METHOD FOR THEIR PRODUCTION AND USE |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
EP0805628B1 (en) | 1995-01-17 | 2003-05-02 | Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6121022A (en) * | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US5916597A (en) | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
JP2000506165A (en) | 1996-03-04 | 2000-05-23 | ザ ペン ステイト リサーチ ファウンデーション | Materials and Methods for Enhancing Cell Internalization |
WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
EP0904107B1 (en) * | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
JP2000508522A (en) | 1996-03-22 | 2000-07-11 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | Apoptosis-inducing molecule II |
WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
DK1500329T3 (en) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Human antibodies that specifically bind TNF-alpha |
ATE287257T1 (en) | 1997-01-16 | 2005-02-15 | Massachusetts Inst Technology | PREPARATION OF PARTICLE-CONTAINING MEDICINAL PRODUCTS FOR INHALATION |
US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CA2286879C (en) | 1997-04-14 | 2003-12-16 | Peter Kufer | Novel method for the production of anti-human antigen receptors and uses thereof |
DK0979281T3 (en) * | 1997-05-02 | 2005-11-21 | Genentech Inc | Process for the preparation of multispecific antibodies with heteromultimers and common components |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6133166A (en) | 1997-07-01 | 2000-10-17 | The Procter & Gamble Company | Cleaning articles comprising a cellulosic fibrous structure having discrete basis weight regions treated with a high internal phase inverse emulsion |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (en) | 1997-10-23 | 2000-04-17 | Biogram Ab | Active substance encapsulation process in a biodegradable polymer |
EP1042343B1 (en) | 1997-11-03 | 2008-01-23 | Human Genome Sciences, Inc. | Vegi, an inhibitor of angiogenesis and tumor growth |
CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
ATE238768T1 (en) | 1998-06-24 | 2003-05-15 | Advanced Inhalation Res Inc | LARGE POROUS PARTICLES EXPECTED FROM AN INHALER |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US6572856B1 (en) * | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
KR100940380B1 (en) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | Polypeptide Variants with Altered Effector Function |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
DE60142614D1 (en) | 2000-01-27 | 2010-09-02 | Medimmune Inc | INITÄT |
US7229619B1 (en) * | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
DK1252192T3 (en) | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Enhancement of the serum half-life of antibody-based fusion proteins |
US7700735B2 (en) | 2000-03-01 | 2010-04-20 | Medimmune, Llc | High potency recombinant antibodies and method for producing them |
JP2003531149A (en) * | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | Enhancement of antibody-derived immune response |
US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
AU2002248184C1 (en) * | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
EP1497318A4 (en) | 2001-04-18 | 2006-03-01 | Dyax Corp | Binding molecules for fc-region polypeptides |
US6911321B2 (en) | 2001-12-19 | 2005-06-28 | Genentech, Inc. | Non-human primate Fc receptors and methods of use |
US7219797B2 (en) * | 2002-01-14 | 2007-05-22 | Alliance Packaging Llc. | Box with insert that extends from a side and that divides the box into compartments and methods for forming and using |
US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
ES2381617T5 (en) | 2002-08-14 | 2016-02-24 | Macrogenics, Inc. | Specific antibodies against FcgammaRIIB and its procedures for use |
EP2298805A3 (en) | 2002-09-27 | 2011-04-13 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
SI1562972T1 (en) | 2002-10-15 | 2010-12-31 | Facet Biotech Corp | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
AU2005302453A1 (en) | 2004-10-29 | 2006-05-11 | Medimmune, Llc | Methods of preventing and treating RSV infections and related conditions |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
EP2373689A1 (en) | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
-
2001
- 2001-12-12 AU AU2002248184A patent/AU2002248184C1/en not_active Expired
- 2001-12-12 ES ES10010679T patent/ES2727425T3/en not_active Expired - Lifetime
- 2001-12-12 EP EP10010679.8A patent/EP2341060B1/en not_active Expired - Lifetime
- 2001-12-12 EP EP01997063A patent/EP1355919B1/en not_active Expired - Lifetime
- 2001-12-12 EP EP10010681A patent/EP2357187A1/en not_active Withdrawn
- 2001-12-12 CA CA2431600A patent/CA2431600C/en not_active Expired - Lifetime
- 2001-12-12 JP JP2002561487A patent/JP4336498B2/en not_active Expired - Lifetime
- 2001-12-12 AT AT01997063T patent/ATE489395T1/en active
- 2001-12-12 ES ES10010680.6T patent/ES2649037T3/en not_active Expired - Lifetime
- 2001-12-12 EP EP10010680.6A patent/EP2354149B1/en not_active Expired - Lifetime
- 2001-12-12 DK DK01997063.1T patent/DK1355919T3/en active
- 2001-12-12 DE DE60143544T patent/DE60143544D1/en not_active Expired - Lifetime
- 2001-12-12 EP EP19153658.0A patent/EP3569610A3/en not_active Withdrawn
- 2001-12-12 WO PCT/US2001/048432 patent/WO2002060919A2/en active Search and Examination
- 2001-12-12 PT PT01997063T patent/PT1355919E/en unknown
- 2001-12-12 US US10/020,354 patent/US7083784B2/en not_active Expired - Lifetime
-
2006
- 2006-04-03 US US11/397,328 patent/US7670600B2/en not_active Expired - Lifetime
-
2007
- 2007-01-03 US US11/649,455 patent/US7704497B2/en not_active Expired - Lifetime
- 2007-08-27 JP JP2007219930A patent/JP4336376B2/en not_active Expired - Lifetime
-
2009
- 2009-05-08 JP JP2009113588A patent/JP5265446B2/en not_active Expired - Lifetime
-
2010
- 2010-01-04 JP JP2010000073A patent/JP5444010B2/en not_active Expired - Lifetime
- 2010-01-21 US US12/691,433 patent/US8012476B2/en not_active Expired - Fee Related
-
2011
- 2011-02-24 CY CY20111100229T patent/CY1111283T1/en unknown
- 2011-07-27 US US13/192,429 patent/US8323962B2/en not_active Expired - Lifetime
-
2012
- 2012-10-24 US US13/659,144 patent/US8475792B2/en not_active Expired - Lifetime
-
2013
- 2013-05-20 US US13/898,042 patent/US8795661B2/en not_active Expired - Fee Related
- 2013-08-16 JP JP2013169026A patent/JP6125949B2/en not_active Expired - Lifetime
-
2014
- 2014-06-20 US US14/310,507 patent/US9562100B2/en not_active Expired - Lifetime
-
2015
- 2015-07-13 JP JP2015139342A patent/JP6268127B2/en not_active Expired - Lifetime
-
2016
- 2016-12-21 JP JP2016247406A patent/JP2017079771A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043713A1 (en) * | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8734791B2 (en) | 2002-03-01 | 2014-05-27 | Xencor, Inc. | Optimized fc variants and methods for their generation |
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US9193798B2 (en) | 2002-09-27 | 2015-11-24 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8093359B2 (en) | 2002-09-27 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8858937B2 (en) | 2002-09-27 | 2014-10-14 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8383109B2 (en) | 2002-09-27 | 2013-02-26 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US9353187B2 (en) | 2002-09-27 | 2016-05-31 | Xencor, Inc. | Optimized FC variants and methods for their generation |
US8809503B2 (en) | 2002-09-27 | 2014-08-19 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8937158B2 (en) | 2003-03-03 | 2015-01-20 | Xencor, Inc. | Fc variants with increased affinity for FcγRIIc |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8735545B2 (en) | 2003-03-03 | 2014-05-27 | Xencor, Inc. | Fc variants having increased affinity for fcyrllc |
US8852586B2 (en) | 2004-11-12 | 2014-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8883973B2 (en) | 2004-11-12 | 2014-11-11 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8338574B2 (en) | 2004-11-12 | 2012-12-25 | Xencor, Inc. | FC variants with altered binding to FCRN |
US8324351B2 (en) | 2004-11-12 | 2012-12-04 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US9574006B2 (en) | 2005-10-06 | 2017-02-21 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8524867B2 (en) | 2006-08-14 | 2013-09-03 | Xencor, Inc. | Optimized antibodies that target CD19 |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002060919A3 (en) | Molecules with extended half-lives, compositions and uses thereof | |
AT500379B1 (en) | TAU PROTEINS | |
DK1135498T3 (en) | Antibody variants with higher binding affinity than parental antibodies | |
BR0314093A (en) | Modified transferrin-antibody fusion proteins | |
DE69807679T2 (en) | COMPOSITIONS OF CONJUGATES OF THE STABLE, ACTIVE, HUMAN OB PROTEINS WITH THE FC CHAIN OF IMMUNOGLOBULINES AND RELATED PROCEDURES | |
WO2003060080A3 (en) | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them | |
BR9916853A (en) | Human monoclonal antibodies to ctla-4 | |
WO2003070760A3 (en) | Anti-amyloid beta antibodies and their use | |
WO2000078344A8 (en) | Prion protein peptides and uses thereof | |
WO2002074337A8 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
NZ596865A (en) | Single-chain multivalent binding proteins with effector function | |
WO2002020569A3 (en) | Mammalian genes; related reagents and methods | |
UA89017C2 (en) | HUMAN ANTIBODY THAT SPECIFICALLY BINDS TO hTNFSF13B | |
WO2006083964A3 (en) | Modified fusion molecules for treatment of allergic disease | |
WO2005051998A3 (en) | Antibodies binding to a c-terminal fragment of apolipoprotein e | |
ATE148168T1 (en) | MONOCLONAL ANTIBODIES | |
WO2005030793A3 (en) | Antibodies which bind human cxcr3 | |
ATE260977T1 (en) | IMMUNOGLOBULIN-BINDING PROTEINS | |
WO2001057219A3 (en) | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods | |
WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases | |
WO2004100882A3 (en) | Inhibition of drug binding to serum albumin | |
WO2002020614A3 (en) | Endoglin-specific polypeptide, production and use thereof | |
WO2001002429A3 (en) | Angiopoietin-6 and uses thereof | |
WO2001012806A3 (en) | Odorant-binding human proteins fixing hydrophobic ligands: polypeptides and polynucleotides coding for said polypeptides and uses thereof | |
WO2003014344A3 (en) | Expression of modified antibodies in avian cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002561487 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2431600 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002248184 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001997063 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001997063 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2002248184 Country of ref document: AU Date of ref document: 20011212 Kind code of ref document: B |